338 related articles for article (PubMed ID: 22411952)
1. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
[TBL] [Abstract][Full Text] [Related]
2. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
End D; Molina A; Todd M; Meyers ML
Cancer Res; 2013 May; 73(9):2926. PubMed ID: 23610449
[No Abstract] [Full Text] [Related]
3. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
4. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
5. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
6. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
[TBL] [Abstract][Full Text] [Related]
11. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
13. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
Grist E; de Bono JS; Attard G
J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
Lim AC; Attard G
Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
[TBL] [Abstract][Full Text] [Related]
15. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
16. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
O'Neill D; Jones D; Wade M; Grey J; Nakjang S; Guo W; Cork D; Davies BR; Wedge SR; Robson CN; Gaughan L
Oncotarget; 2015 Sep; 6(28):26029-40. PubMed ID: 26267320
[TBL] [Abstract][Full Text] [Related]
17. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
18. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
[TBL] [Abstract][Full Text] [Related]
19. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
20. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
